Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-01-09FDA Approved: FLUOXETINE — Supplemental Application (Vensun Pharmaceuticals, Inc.)
FDA approved a supplemental application for fluoxetine hydrochloride from Vensun Pharmaceuticals, Inc., granting approval of a generic fluox…
-
FDA approval · 2024-01-03FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fluoxetine hydrochloride.
-
FDA approval · 2023-12-19FDA Approved: FLUOXETINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Magnetic Stimulation [Phase 3]
A Phase 3 clinical trial updating on transcranial magnetic stimulation for obsessive-compulsive disorder.
-
FDA approval · 2023-12-11FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for fluvoxamine maleate (Endo USA, Inc.).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-30Clinical Trial Update: A Clinical Trial of Fecal Microbiota Transplantation in a Population With Obsessive-compulsive Disorder [Phase 2]
Phase 2 clinical trial investigating fecal microbiota transplantation for obsessive-compulsive disorder.
-
FDA approval · 2023-11-20FDA Approved: FLUOXETINE — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for fluoxetine submitted by Endo USA, Inc., resulting in regulatory changes to the product's sta…
-
FDA approval · 2023-11-15FDA Approved: FLUOXETINE — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for fluoxetine (generic) from Micro Labs Limited under an ANDA.
-
FDA approval · 2023-09-22FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for sertraline hydrochloride from Granules Pharmaceuticals Inc. The action confirms continued approv…
-
FDA approval · 2023-09-21FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Supplemental Application (Lifestar Pharma LLC)
FDA approved a supplemental application for clomipramine hydrochloride from Lifestar Pharma LLC, resulting in a generic version of the antid…
-
FDA approval · 2023-09-19FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for fluoxetine submitted by Aurobindo Pharma Limited. This action updates the regulatory status …
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: iTBS-DCS in Obsessive Compulsive Disorder [Phase 2]
Phase 2 clinical trial update for iTBS-DCS in obsessive-compulsive disorder.
-
FDA approval · 2023-08-31FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for fluvoxamine maleate submitted by Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2023-08-30Clinical Trial Update: Overlapping Neural Circuits in Pediatric OCD [NA]
A completed clinical trial investigating overlapping neural circuits in pediatric obsessive-compulsive disorder; results posted in 2023.
-
FDA approval · 2023-08-21FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
The FDA approved a supplemental application for fluoxetine hydrochloride (generic fluoxetine) submitted by PAI Holdings, dba PAI Pharma.
-
FDA approval · 2023-08-21FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for fluoxetine hydrochloride (ANI Pharmaceuticals, Inc.), indicating approval of changes to an alrea…
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for fluoxetine from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-08-18FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for sertraline hydrochloride (generic) manufactured by Mylan Pharmaceuticals Inc.
-
FDA approval · 2023-08-18FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for a generic fluoxetine hydrochloride product from Lannett Company, Inc.
-
FDA label_change · 2023-08-18FDA Approved: FLUOXETINE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC)
FDA approved a supplemental application for Fluoxetine to update the labeling. The applicant is Chartwell Governmental & Specialty RX, LLC.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for the generic fluoxetine from Aurobindo Pharma Limited, allowing continued marketing of a fluo…
-
FDA label_change · 2023-08-18FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for fluvoxamine maleate (generic fluvoxamine) from Endo USA, Inc., updating the drug's labeling.
-
FDA approval · 2023-08-18FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma's supplemental application to market a generic fluvoxamine maleate product.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for fluoxetine hydrochloride from Endo USA, Inc.